drugset / Trial / NCT05895955
Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais
Phase 1/2
Active not recruiting
290 enrolled
Mahidol University
The Government Pharmaceutical Organization · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The study is aim to evaluate the safety and immunogenicity of one dose TetraFluvac TF vaccine (15 μg HA per strain per dose) of the GPO seasonal quadrivalent inactivated split virion influenza vaccine in healthy adults aged 18 years and above over 90 days post-injection.
Timeline
- Start
- 2023-11-04
- Primary completion
- 2024-03-25
- Completion
- 2025-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Inactivated Trivalent Influenza Vaccine | Vaccine | 0.5 ml | Intramuscular |
| Subject | TetraFluvac TF vaccine | Vaccine | 0.5 ml | Intramuscular |